Novartis: FDA approves Adamis' allergy treatment
(CercleFinance.com) - The US Food and Drug Administration has approved Adamis' Symjepi, an injectable drug that will be distributed by Novartis' Sandoz, for the emergency treatment of allergic reactions, including anaphylaxis, a serious condition that may result indeath.
Sandoz recently announced a distribution and commercialization agreement with Adamis to market Symjepi in the US.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Sandoz recently announced a distribution and commercialization agreement with Adamis to market Symjepi in the US.
Copyright (c) 2018 CercleFinance.com. All rights reserved.